



ANTI-HYPERLIPIDEMIC POTENTIAL OF A COMBINATION OF *Zingiber officinale* Roscoe, *Allium sativum* L., *Citrus lemon* (L.) Osbeck, HONEY AND *Malus domestica* Borkh. CIDER VINEGAR

By

KOKILA VANI A/P PERUMAL

Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in Fulfilment of the Requirements for the Degree of Master of Science

August 2022

FPSK (m) 2022 42

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in
fulfilment of the requirement for the degree of Master of Science

ANTI-HYPERLIPIDEMIC POTENTIAL OF A COMBINATION OF *Zingiber officinale* Roscoe, *Allium sativum* L., *Citrus lemon* (L.) Osbeck, HONEY AND *Malus domestica* Borkh. CIDER VINEGAR

By

KOKILA VANI A/P PERUMAL

August 2022

Chair : Assoc. Prof. Hasnah Bahari, PhD
Faculty : Medicine and Health Sciences

Intervention of herbal combination is widely used to decrease the risk of metabolic disorders such as cardiovascular diseases, hyperlipidemia, diabetes, and obesity. Hyperlipidemia is known as an abnormal lipid metabolism presents in the bloodstream which associated with co-morbidities and mortalities that grossly rising worldwide. The study aims to investigate the anti-hyperlipidemia activities of a combination of ZACAH mixture (*Zingiber officinale* Roscoe (ginger), *Allium sativum* L. (garlic), *Citrus lemon* (L.) Osbeck, Honey, and *Malus domestica* Borkh. Cider Vinegar in hyperlipidemic rats. High-performance liquid chromatography (HPLC) was performed to identify the phytochemical component that presents in the ZACAH mixture. 36 Sprague dawley (SD) rats were divided into 6 groups. ZACAH mixture (1ml/kg, 3 ml/kg, 5 ml/kg) was administered along with a high cholesterol diet (HCD) via oral gavage, daily for 18 weeks. Simvastatin 10 mg/kg was used as a standard drug. At end of week 18, the rats were sacrificed and blood and organs were collected for further experiments. The blood collection was performed for lipid profile (TC, TG, LDL), blood toxicity (Creatinine, AST, ALT), and enzymatic activity (HMG-CoA reductase, LCAT, ACAT2). Besides, liver, kidney and adipose tissue were performed for histological examination by using hematoxylin & eosin (H&E) stain. ZACAH mixture had ORAC value 2000 $\mu\text{mol TE}/100\text{ mL}$, TPC (7537 \pm 54.5mg/100g GAE), 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging activity (27.34 \pm 2.71%), Elastase inhibitory assay (29.29 \pm 1.65%) and Lipoxxygenase inhibitory assay (98.58 \pm 1.42%). The phytochemical component found in the ZACAH mixture is hesperidin. Bodyweight, total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) reduced and an increase in high density lipoprotein (HDL) was observed in ZACAH mixture treated groups compared to the positive control (PC). ZACAH mixture treated groups reduced HMG-CoA reductase and ACAT2 activity led to a reduction of TC, TG, LDL and an increase in HDL. Histological examinations revealed that lipid accumulation was reduced in the liver tissue and the size of adipocytes was

suppressed in the ZACAH mixture treated group as compared to the PC group. The findings demonstrate that the ZACAH mixture at 5ml/kg BW significantly ($p<0.05$) has a strong hyperlipidemia activity that can be an alternative approach to combat hyperlipidemia treatment.

Keywords: ZACAH mixture, Hyperlipidemia, High cholesterol diet



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia
sebagai memenuhi keperluan untuk ijazah Master Sains

**POTENSI ANTI-HIPERLIPIDEMIK GABUNGAN *Zingiber officinale*
Roscoe, *Allium sativum* L., *Citrus lemon* (L.) Osbeck, MADU
DAN CUKA SIDER *Malus domestica* Borkh**

Oleh

KOKILA VANI A/P PERUMAL

Ogos 2022

Pengerusi : Prof. Madya Hasnah Bahari, PhD
Fakulti : Perubatan dan Sains Kesihatan

Gabungan herba digunakan secara meluas untuk mengurangkan risiko gangguan metabolik seperti penyakit kardiovaskular, hiperlipidemia, kencing manis, dan obesiti. Hiperlipidemia dikenali sebagai metabolisme lipid yang tidak normal yang terdapat dalam aliran darah yang dikaitkan dengan komorbiditi dan kematian yang meningkat secara mendadak di seluruh dunia. Kajian ini bertujuan untuk menyiasat aktiviti anti-hiperlipidemik gabungan ZACAH daripada (*Zingiber Officinale* Roscoe (halia), *Allium sativum* L. (bawang putih), limau sitrus, Madu, dan cuka *Malus domestica* (epal) dalam tikus hiperlipidemik. 36 ekor tikus Sprague dawley (SD) dibahagikan kepada 6 kumpulan. Gabungan ZACAH (1mg/kg, 3 mg/kg, 5 mg/kg) diberikan bersama diet kolesterol tinggi (HCD) melalui gavage oral, setiap hari untuk 18 minggu. Simvastatin 10 mg/kg mengikut berat badan digunakan sebagai ubat standard. Pada akhir minggu ke-18, tikus telah dikorbankan dan darah serta organ dikumpulkan untuk eksperimen selanjutnya. Pengumpulan darah dilakukan untuk profil lipid (TC, TG, LDL), ketoksikan darah (Creatinine, AST, ALT), dan aktiviti enzimatik (HMG-CoA reductase, LCAT, ACAT2). Selain itu, hati, buah pinggang dan tisu adipos telah dilakukan untuk pemeriksaan histologi menggunakan hematoxylin & eosin (H &E). Campuran ZACAH mempunyai nilai ORAC 2000 $\mu\text{mol TE}/100\text{ mL}$, TPC ($7537 \pm 54.5\text{mg}/100\text{g GAE}$), 2,2-diphenyl-1-picrylhydrazyl (DPPH) aktiviti penghapusan radikal bebas ($27.34 \pm 2.71\%$), akitiviti elastase ($29.29 \pm 1.65\%$) dan ujian perencatan lipoxxygenase ($98.58 \pm 1.42\%$). Komponen fitokimia yang terdapat dalam campuran ZACAH ialah hesperidin. Kumpulan rawatan campuran ZACAH mengurangkan aktiviti HMG-CoA reduktase dan ACAT2 membawa kepada pengurangan tahap TC, TG, LDL dan peningkatan dalam HDL. Pemeriksaan histologi mendedahkan bahawa pengumpulan lipid dikurangkan dalam tisu hati dan saiz adiposit berkurang dalam kumpulan rawatan campuran ZACAH berbanding dengan kumpulan PC. Penemuan menunjukkan bahawa campuran ZACAH pada 5ml/kg berat badan (BW) mempunyai aktiviti hiperlipidemia yang kuat yang boleh menjadi pendekatan alternatif untuk memerangi rawatan hiperlipidemia.

ACKNOWLEDGEMENTS

First, I would like to express my appreciation to the Department of Human Anatomy and Physiology, Universiti Putra Malaysia for giving me an opportunity to hands on this project. My sincere thanks go to my supervisor Assoc. Prof. Dr Hasnah Bahari, has supported me throughout this research without failed. Thank you Dr Hasnah for your guidance, encouraging words and thoughtful, detailed feedback that have been very important to me.

I would also like to thank Mr Santhra Segaran balan, Assoc Prof. Dr. Norshafarina and Assoc Prof. Dr. Maizaton for all the assistance that has been provided. Very special thanks to teammate Kasturi who helped me with this project. An honourable mention goes to my family who is my number one supporter, for having faith, giving me abundant of love and concern throughout the years of hard work. Last but not least, I would like to thank all those who have been involved directly and indirectly throughout this journey.

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

Hasnah Bahari, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Maizatun Atmadini bt Abdullah, MBBS, MPath, PhD

Associate Professor (Medical)
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

Norshafarina Shari@Kamarudin, PhD

Associate Professor
Health and Life Sciences
Management and Science University
(Member)

ZALILAH MOHD SHARIFF, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 09 March 2023

Declaration by the Graduate Student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: _____ Date: _____

Name and Matric No.: Kokila Vani Perumal

Declaration by Members of the Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: _____
Name of Chairman
of Supervisory
Committee: Assoc. Prof. Dr Hasnah Bahari

Signature: _____
Name of Member of
Supervisory
Committee: Assoc Prof. Dr. Norshafarina
Shari@Kamarudin,

Signature: _____
Name of Member of
Supervisory
Committee: Assoc Prof. Dr. Maizatun
Atmadini bt Abdullah

TABLE OF CONTENTS

	Page
ABSTRACT	i
ABSTRAK	iii
ACKNOWLEDGEMENTS	iv
APPROVAL	v
DECLARATION	vii
LIST OF TABLES	xi
LIST OF FIGURES	xiii
LIST OF ABBREVIATIONS	xv
 CHAPTER	
1 INTRODUCTION	1
2 LITERATURE REVIEW	7
2.1 Hyperlipidemia	7
2.2 Complications of hyperlipidemia	8
2.3 Cholesterol and lipoproteins	8
2.4 Cholesterol biosynthesis	9
2.5 Liver function test (AST, ALT) and renal function test (Creatinine)	10
2.6 Enzyme related to hyperlipidemia	10
2.6.1 HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A	10
2.6.2 Lecithin—cholesterol acyltransferase (LCAT)	11
2.6.3 Acyl-CoA:cholesterol acyltransferase 2 (ACAT2	12
2.7 Current treatment of hyperlipidemia	12
2.8 Combination of herbal	13
2.8.1 <i>Zinger officinale</i>	13
2.8.2 <i>Allium sativum</i>	14
2.8.3 <i>Citrus lemon</i>	14
2.8.4 <i>Honey</i>	14
2.8.5 Apple cider vinegar	15
3 MATERIALS AND METHODS / METHODOLOGY	16
3.1 Preparation of ZACAH mixture	16
3.2 Determination of antioxidant capacities	16
3.2.1 ORAC (Oxygen radical absorbance capacity) assay	16
3.2.2 Determination of total phenolic content (TPC)	16
3.2.3 Determination of Elastase inhibitory assay	17

3.2.4	Determination of DPPH radical scavenging assay	17
3.2.5	Identification of hesperidin	17
3.3	Preparation high cholesterol diet (HCD)	18
3.4	Ethical consideration	18
3.5	Experimental animals	18
3.6	Analyses	19
3.6.1	Measurement of bodyweight	19
3.6.2	Measurement of caloric intake	19
3.6.3	Measurement of organ weight and tissue collection	19
3.6.4	Measurement of biochemical analysis	19
3.6.5	Determination of enzymatic activity	19
3.7	Histopathological analyses	20
3.8	Statistical analysis	21
3.9	Framework	21
4	RESULTS AND DISCUSSION	
4.1	Antioxidant capacity of ZACAH mixture	22
4.2	Identification of Phenolic Compounds of ZACAH mixture by HPLC	22
4.3	The effect of ZACAH mixture on bodyweight	23
4.4	The effect of ZACAH mixture on caloric intake	24
4.5	The effect of ZACAH mixture on bodyweight at death, organ weight, and relative weight of organ weight	25
4.6	The effect of ZACAH mixture on lipid profile	27
4.6.1	Total cholesterol (TC)	27
4.6.2	Triglycerides (TG)	28
4.6.3	LDL	29
4.6.4	HDL	30
4.7	The effect of ZACAH mixture on liver and kidney function tests	31
4.7.1	Creatinine	31
4.7.2	Aspartate aminotransferase (AST)	31
4.7.3	Alanine aminotransferase (ALT)	32
4.8	The effect of ZACAH mixture on enzyme assays	33
4.8.1	The effect of ZACAH mixture on HMG-CoA reductase	33
4.8.2	The effect of ZACAH mixture on Lecithin-cholesterol acyltransferase (LCAT)	34
4.8.3	The effect of ZACAH mixture on Acyl-coA cholesterol acyltransferase 2 (ACAT2)	35

4.9	The effect of ZACAH mixture on histology analysis of liver	35
4.10	The effect of ZACAH mixture on histology analysis of adipose tissue	36
4.11	The effect of ZACAH mixture on histology analysis of kidney	37
5	DISCUSSION	
5.1	Effect of ZACAH mixture on antioxidant capacity	39
5.2	Effect of ZACAH mixture on bodyweight, caloric intake, organ weight	39
5.3	Effect of ZACAH mixture on lipid profile and kidney and liver enzyme	40
5.4	Effect of ZACAH mixture on histology	41
5.5	Effect of ZACAH mixture on enzymatic activity	42
6	CONCLUSION AND RECOMMENDATIONS FOR FUTURE RESEARCH	43
	REFERENCES	44
	APPENDICES	54
	BIODATA OF STUDENT	63
	LIST OF PUBLICATIONS	64

LIST OF TABLES

Table		Page
2.1	Classification of normal and abnormal level of lipids	9
2.2	Summary of the drugs and effects of drugs used in the treatment of hyperlipidemia	13
3.1	Nutritional composition of ZACAH mixture	16
3.2	Calories composition of HCD	18
3.3	Experimental group	18
3.4	The fat deposition scoring of the adipose tissue	20
4.1	Antioxidant Capacity of ZACAH mixture	22
4.2	Quantitative analysis data of hesperidin in ZACAH mixture	23
4.3	The effect of ZACAH mixture on caloric intake, and bodyweight at week 18	25
4.4	The effect of ZACAH mixture on organ weight, and relative weight of organ weight	27

LIST OF FIGURES

Figure		Page
2.1	Overview cholesterol biosynthesis pathway	10
2.2	HMG-CoA reductase	11
2.3	LCAT pathway	11
3.1	Framework of ZACAH mixture on SD rats	21
4.1	High-performance liquid chromatogram (HPLC) of ZACAH mixture	23
4.2	The effect of ZACAH mixture on weekly bodyweight	24
4.3	The effect of ZACAH mixture on weekly caloric intake	25
4.4A	The effect of ZACAH mixture on total cholesterol	28
4.4B	The effect of ZACAH mixture on triglyceride (TG)	29
4.4C	The effect of ZACAH mixture on LDL	30
4.4D	The effect of ZACAH mixture on lipid profile on high- density lipoprotein (HDL)	30
4.5A	The effect of ZACAH mixture on creatinine	31
4.5B	The effect of ZACAH mixture on Aspartate aminotransferase (AST).	32
4.5C	The effect of ZACAH mixture on Alanine aminotransferase (ALT)	33
4.6A	The effect of ZACAH mixture on HMG-CoA reductase activity	34
4.6B	The effect of ZACAH mixture on LCAT activity	34
4.6C	The effect of ZACAH mixture on ACAT2 activity	35

4.7	The effect of ZACAH mixture on histological changes of liver tissues	36
4.8	The effect of ZACAH mixture on histological changes of adipose tissues	37
4.9	The effect of ZACAH mixture on histological changes of kidney tissues	38



LIST OF ABBREVIATIONS

ABCA1	ATP-binding cassette transporter A1
ACAT2	Acyl-coa cholesterol acyltransferase 2
AST	Aspirate aminotransferase
ALT	Alanine aminotransferase
BW	Bodyweight
CE	Cholesterol ester
DC	Drug control
DMAPP	Dimethylallyl diphosphate
DMSO	Dimethyl sulfoxide
DPPH	2,2-diphenyl-1-picrylhydrazyl
FC	Free cholesterol
FPP	Farnesyl diphosphate
GPP	Geranyl pyrophosphate
HCD	High cholesterol diet
HDL	High-density lipoprotein
H&E	Hematoxylin & eosin
HMG- CoA	3-Hydroxy-3-methylglutaryl CoA
HPLC	High-performance liquid chromatography
IPP	isopentenyl pyrophosphate
LCAT	Lecithin cholesterol acyltransferase
LDL	Low-density lipoprotein
LSD	Least significant difference
NBF	Neutral buffered formalin
NC	Negative control
OD	Optical density

ORAC	Oxygen radical absorbance capacity
PC	Positive control
RCT	Reverse cholesterol transport
SANA	Succ-(Ala)3-pnitroanilide
SD	Sprague dawley
SEM	Standard error of mean
TC	Total cholesterol
TG	Triglyceride
TPC	Total phenolic content
TX	Treatment
UPM	Universiti Putra Malaysia
VLDL	Very-low density lipoprotein
ZACAH	<i>Zingiber Officinale</i> , <i>Allium Sativum</i> , <i>Citrus Lemon</i> , Honey and <i>Malus Domestica</i> Cider Vinegar

CHAPTER 1

INTRODUCTION

1.1 Background of study

Hyperlipidemia is defined as an elevated amount of lipids in the bloodstream that rise in low-density lipoprotein cholesterol (LDL), total cholesterol (TC), and triglyceride (TG) levels and lower the high-density lipoprotein cholesterol (HDL) (Gill et al., 2021; Hill & Bordini, 2022). As stated in National Health and Morbidity Survey 2019, an unhealthy amount of cholesterol is taken into account when it exceeds 5.2 mmol/L or higher. There is a primary and secondary types of hyperlipidemia. The primary type of hyperlipidemia happens due to consuming high fats and cholesterol-rich foods as well as genetic defects. While the secondary type of hyperlipidemia happens due to metabolic disorders and endocrine diseases (Nelson R, 2013). The complications that caused by hyperlipidemia are atherosclerosis, cardiovascular diseases, hypertension, and diabetes mellitus.

The prevalence of hyperlipidemia in Malaysia is major contributor that lead to cardiovascular disease (Ministry of Health Science, 2015). 8 million adults have a high level of cholesterol where 45% of females and 32% of males (NHMS, 2019). According to World Health Organization (WHO), approximately 2.6 million death are caused annually due to the rise of cholesterol. By the year 2030, it will be the world's biggest killer that affecting about 23.6 million people worldwide (WHO, 2015). Hyperlipidemia is associated with increase levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL) and subsequently dropped in high-density lipoprotein (HDL). Cholesterol is known as a component that regulates the fluidity and permeability of the cell membranes. Physiologically, cells are protected from the intracellular excessive deposition of cholesterol by regulating its synthesis, influx and efflux (Han, Yeung, Ip, & Mak, 2018). The primary rate-limiting enzyme for the cholesterol synthesis is 3-Hydroxy-3-methylglutaryl CoA (HMG- CoA) reductase. While cholesterol influx is facilitated by the LDL receptor, the efflux is majorly regulated by ATP-binding cassette transporter A1 (ABCA1) (Weibel et al., 2014). Alteration in this mechanism leads to excessive deposition of cholesterol, which may subsequently result in end-organ damage, characterized by increased necrosis and cell death (Li et al., 2015).

The available synthetic lipid-lowering drugs are statins and fibrates that are used to treat hyperlipidemia. Statins are widely used to reduce cholesterol levels via the cholesterol biosynthetic pathway by inhibiting HMG- CoA reductase. However, most of the drugs consist of undesirable side effects including liver poisoning, liver dysfunction, reduced liver enzyme, myopathy and complications with long term use (Ballantyne et al., 2003; Xu et al., 2014). Therefore, the use of natural and herbal medicine products have been increased in the development

of hyperlipidemia drugs due to fewer side effects, low toxicity (Perumal et al., 2019) cheap and easily available. On the other hand, phytochemicals, and bioactive components of herbs or plant origin help in the prevention of diseases (Sen, Chakraborty, Sridhar, Reddy, & De, 2010). In spite of the available drugs are effective but the side effects and mortality that caused by hyperlipidemia are worried high.

Nowadays, modern medicine highly substitutes natural and herbal sources. Natural and herbal sources that consist of *Zingiber officinale* (ginger), *Allium sativum* (garlic), Citrus lemon, *Malus domestica* (apple) vinegar and Honey [ZACAH mixture] are widely used for centuries due to their rich sources and numerous treatments including hyperlipidemia, obesity, and cardiovascular (Saravanan, Ponmurugan, Deepa, & Senthilkumar, 2014).

Zinger officinale is a ginger that belongs to zingi-beraceae family that is used as dietary supplement in food and drinks and has ability to decrease lipid concentration (Bhandari, Kanojia, & Pillai, 2005; Singletary, 2010). *Allium sativum* is a garlic that originated in Central Asia (Hosseini & Hosseinzadeh, 2015) and used in food as a spice and home remedies as a medicinal purpose for various diseases (Mikaili, Maadirad, Moloudizargari, Aghajanshakeri, & Sarahroodi, 2013). Citrus lemon comes from the Rutaceae family which is originated from tropical and subtropical Southeast Asia (Chaturvedi & Shrivastava Suhane, 2016). It is well known for sore throat soothing with the mixture of honey, helps in weight loss, is anti-inflammatory, and balances pH in the body (Chaturvedi & Shrivastava Suhane, 2016).

Honey is a sweetener that has vitamins, minerals, acids as well as enzymes (Chepulis & Starkey, 2008) that enhanced antioxidant capacity, lipid regulation, and improve the immune system (Cortés, Vigil, & Montenegro, 2011). Apple cider vinegar is made by fermenting apples that are consumed as flavoring as well as a preservative agent (Khezri, Saidpour, Hosseinzadeh, & Amiri, 2018). Into the bargain, compounds that present in ZACAH mixture to have been reported have anti-hyperlipidemia, anti-oxidant, and cardio protective properties (Naseem, Shamim, & Khan, 2016) (Ajamzibad, Baloochi Beydokhti, Mohtasham, & Nematollahi, 2021).

In spite of medicinal properties that mentioned, there is insufficient studies on the hyperlipidemia activity of ZACAH mixture. Moreover, the potential of ZACAH mixture as HMG-CoA reductase has not yet been investigated. Therefore, this present study proposed that ZACAH mixture work as a natural cholesterol-lowering agent that interferes with the mevalonate synthesis pathway through the inhibition of HMG-CoA reductase activities.

1.2 Statement of the problem

In spite of medicinal Hyperlipidemia severity is grossly increasing around the world (Hill & Bordon, 2022). Hyperlipidemia treated drugs are available such as statin, bile acid sequestrants, and fibrates that inhibit excess lipid accumulation, cholesterol formation, and activation mevalonate pathway.

Based on GHO (Global health observatory data), hyperlipidemia causes one-third of ischaemic heart disease (WHO, 2015). Besides, 2.6 million deaths were caused by the raised of total cholesterol. Hyperlipidemia major leads to cardiovascular diseases (CVD). This predicted the over the next 10 years, CVD will be the leading cause of death (Jørgensen et al., 2013 ; Shattat, 2015). The highest mortality was found in Eastern Europe and Central Asia (Benjamin et al., 2017).

Drug therapies are available for the management and treatment of lipid and lipoprotein levels in blood but they consist of limitations as well as side effects (Wilkinson, Laffin, & Davidson, 2014). Therefore, medicinal plants are widely used as an alternative treatment for hyperlipidemia due to minimal or no side effects. Isoflavones, phytosterols, saponins, fibres, polyphenols, flavonoids, and ascorbic acid are active compounds that are produced by plants that play a huge responsibility in lipid metabolism (Verma et al., 2010) ; (Bulkus et al., 2010).

1.3 Justification of study

Many researchers have studied widely on a number of herbal combinations to treat diabetes, cardiovascular disease, and microbial activity that lowers total cholesterol, lipoproteins and blood sugar levels (Mothana et al., 2010 ; Bulku et al., 2010). Several Ayurveda drug manufacturers in India have been marketing herbal combination formulation drugs to treat various diseases such as Livergen (Standard Pharmaceuticals) used for liver problems that consist of 6 herbs, Tefroliv (TTK Pharma Pvt. Ltd.) used for hepatic disorders that made of 9 types of herbs and Pankajakasthuri (Herbals India Pvt. Ltd.) used for respiratory infections that have 14 herbs (Visavadiya & Narasimhacharya, 2011). Therefore, the present research aims to find effective combinations of herbals for the management and treatment of hyperlipidemia.

1.4 Objectives

1.4.1 Main objective

The general objective of this study is to determine anti-hyperlipidemic potential of a combination of *Zingiber officinale* Roscoe, *Allium sativum* L., *Citrus lemon* (L.) Osbeck, Honey and *Malus domestica* Borkh. Cider Vinegar (ZACAH) mixture in rats fed with high cholesterol diet.

Specific objectives

1. To determine ORAC (Oxygen radical absorbance capacity) assay, total phenolic content (TPC), elastase inhibitory assay, 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay, and phytochemicals using high-performance liquid chromatography (HPLC) in ZACAH mixture.
2. To measure the effects of ZACAH mixture on body weight, caloric intake and organs weight in rats fed with high cholesterol diet.
3. To determine lipid profiles [total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL)] in rats fed with high cholesterol diet supplemented with ZACAH mixture.
4. To determine liver and kidney function tests [Creatinine, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT)] in rats fed with high cholesterol diet supplemented with ZACAH mixture.
5. To evaluate the effects of ZACAH mixture on cholesterol metabolism [3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, lecithin cholesterol acyltransferase (LCAT), acyl-coa cholesterol acyltransferase 2 (ACAT2)] in rats fed with high cholesterol diet.
6. To identify histological changes of liver, adipose tissue, kidney through Hematoxylin and Eosin (H&E) staining in rats fed with high cholesterol diet supplemented with ZACAH mixture.

1.5 Hypothesis

1. ZACAH mixture reduces the bodyweight, and organ weight in rats fed with high cholesterol diet.
2. ZACAH mixture decreases the lipid profiles [total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL)] and increases the high density lipoprotein (HDL) in rats fed with high cholesterol diet.

3. ZACAH mixture decreases the liver and kidney function tests [Creatinine, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT)] in rats fed with high cholesterol diet.
4. ZACAH mixture reduce the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, acyl-coa cholesterol acyltransferase 2 (ACAT2) and increase lecithin cholesterol acyltransferase (LCAT), in rats fed with high cholesterol diet.
5. ZACAH mixture shows regeneration of liver, adipose tissue, and kidney toward normal architecture in rats fed with high cholesterol diet



REFERENCES

- Al-Amin, Z. M., Thomson, M., Al-Qattan, K. K., Peltonen-Shalaby, R., & Ali, M. (2006). Anti-diabetic and hypolipidaemic properties of ginger (*Zingiber officinale*) in streptozotocin-induced diabetic rats. *British Journal of Nutrition*, 96(04), 660–666.
- Al-Waili, N. S. (2004). Natural Honey Lowers Plasma Glucose, C-Reactive Protein, Homocysteine, and Blood Lipids in Healthy, Diabetic, and Hyperlipidemic Subjects: Comparison with Dextrose and Sucrose. *Journal of Medicinal Food*, 7(1), 100–107.
- Ajamzibad, H., Baloochi Beydokhti, T., Mohtasham, F., & Nematollahi, M. R. (2021). Effects of boiled garlic and Shirazi lemon on blood lipids in hyperlipidemic patients: A quasi-experimental study. *Journal of Herbal Medicine*, 28, 100439.
- Amarenco, P., & Labreuche, J. (2009). Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. *The Lancet Neurology*, 8(5), 453–463.
- Aoshima, H., Tsunoue, H., Koda, H., & Kiso, Y. (2004). Aging of whiskey increases 1,1-diphenyl-2-picrylhydrazyl radical scavenging activity. *Journal of Agricultural and Food Chemistry*, 52(16), 5240–5244.
- Arzanlou, M., & Bohlooli, S. (2010). Introducing of green garlic plant as a new source of allicin. *Food Chemistry*, 120(1), 179–183
- Asdaq SMB. (2015). Antioxidant and hypolipidemic potential of aged garlic extract and its constituent, s-allyl cysteine, in rats. *Evid Based Complement Alternat Med*, 2015, 328545–328552.
- Augusti, K. T., hy Narayanan, A., Pillai, L. S., Ebrahim, R., Sivadasan, R., Sindhu, K. R., Nair, S. S. (2001). *Beneficial effects of garlic (Allium sativum Linn) on rats fed with diets containing cholesterol and either of the oil seeds, coconuts or groundnuts*. *Indian Journal of Experimental Biology*, 39(7), 660–667.
- Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., & Stein, E. A. (2003). Risk for myopathy with statin therapy in high-risk patients. *Archives of internal medicine*, 163(5), 553- 564.
- Ballantyne, C. M. (2000). Primary Prevention of Coronary Heart Disease. *The Journal of Clinical Endocrinology & Metabolism*, 85(6), 2089–2092.
- Barbara G Wells, Joseph T DiPiro, Terry L Schwinghammer, Cindy Hamilton (2005). *Pharmacotherapy Handbook*, 6thed. McGraw-Hill publications. p. 92-96

- Barter, P. (2005). The role of HDL-cholesterol in preventing atherosclerotic disease. *European heart journal Supplements*, 7(suppl_F), F4-F8.
- Belay, B., Belamarich, P. F., & Tom-Revzon, C. (2007). The use of statins in pediatrics: knowledge base, limitations, and future directions. *Pediatrics*, 119(2), 370-380.
- Bélichard, P., Pruneau, D., & Zhiri, A. (1993). Effect of a long-term treatment with lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster. *Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism*, 1169(1), 98–102.
- Benavente-García, O., & Castillo, J. (2008). Update on uses and properties of citrus flavonoids: New findings in anticancer, cardiovascular, and anti-inflammatory activity. *Journal of Agricultural and Food Chemistry*, 56(15), 6185–6205.
- Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., & Jiménez, M. C. (2017). Heart disease and stroke statistics-2017 update: a report from the American Heart Association. *Circulation*, 135(10), e146-e603.
- Bhandari, U., Kanojia, R., & Pillai, K. K. (2005). Effect of ethanolic extract of *Zingiber officinale* on dyslipidaemia in diabetic rats. *Journal of Ethnopharmacology*, 97(2), 227–230.
- Blois, M. S. (1958). Antioxidant determinations by the use of a stable free radical. *Nature*, 181(4617), 1199-1200.
- Bulku, E., Zinkovsky, D., Patel, P., Javia, V., Lahoti, T., Khodos, I., Ray, S. D. (2010). A novel dietary supplement containing multiple phytochemicals and vitamins elevates hepatorenal and cardiac antioxidant enzymes in the absence of significant serum chemistry and genomic changes. *Oxidative Medicine and Cellular Longevity*, 3(2), 129– 144.
- Chaturvedi, D., & Shrivastava Suhane, R. R. N. (2016). Basketful Benefit of Citrus Limon. *International Research Journal of Pharmacy*, 7(6), 1–4.
- Chepulis, L., & Starkey, N. (2008). The long-term effects of feeding honey compared with sucrose and a sugar-free diet on weight gain, lipid profiles, and DEXA measurements in rats. *Journal of Food Science*, 73(1).
- Chung, J. Y., & Kim, C. S. (2008). Antioxidant activities of domestic garlic (*Allium sativum* L.) stems from different areas. *Journal of the Korean Society of Food Science and Nutrition*, 37(8), 972–978.
- Chung, S., & Parks, J. S. (2016). Dietary cholesterol effects on adipose tissue inflammation. *Current opinion in lipidology*, 27(1), 19.
- Cortés, M. E., Vigil, P., & Montenegro, G. (2011). The medicinal value of honey: a review on its benefits to human health, with a special focus on its effects

- on glycemic regulation. *International Journal of Agriculture and Natural Resources*, 38(2), 303–317.
- DeBose-Boyd, R. A. (2008). Feedback regulation of cholesterol synthesis: Sterol-accelerated ubiquitination and degradation of HMG CoA reductase. *Cell Research*, 18(6), 609–621.
- De Brum, T. F., Zadra, M., Piana, M., Boligon, A. A., Fröhlich, J. K., De Freitas, R. B., ... & Athayde, M. L. (2013). HPLC analysis of phenolics compounds and antioxidant capacity of leaves of *Vitex megapotamica* (Sprengel) Moldenke. *Molecules*, 18(7), 8342–8357.
- Devaraj, N. K., Mohamed, M., & Hussein, N. (2017). Prevalence, factors influencing and knowledge about adherence to lipid-lowering therapy among hyperlipidemia patients. *Medical Journal of Malaysia*, 72(3), 157–164.
- Diebold, B. A., Bhagavan, N. V., & Guillory, R. J. (1994). Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs. *BBA - General Subjects*, 1200(2), 100–108.
- El-Dakhakhny, M., Mady, N., Lembert, N., & Ammon, H. P. T. (2002). The hypoglycemic effect of *Nigella sativa* oil is mediated by extrapancreatic actions. *Planta Medica*, 68(5), 465–466.
- Feingold, K. R., & Grunfeld, C. (2000). *Introduction to Lipids and Lipoproteins*. Endotext. MDText.com, Inc. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/26247089>
- Fushimi, T., Suruga, K., Oshima, Y., Fukiharu, M., Tsukamoto, Y., & Goda, T. (2006). Dietary acetic acid reduces serum cholesterol and triacylglycerols in rats fed a cholesterol-rich diet. *British Journal of Nutrition*, 95(5), 916–924.
- Gao, W., He, H. W., Wang, Z. M., Zhao, H., Lian, X. Q., Wang, Y. S., Wang, L. S. (2012). Plasma levels of lipometabolism-related miR-122 and miR- 370 are increased in patients with hyperlipidemia and associated with coronary artery disease. *Lipids in Health and Disease*, 11, 55.
- Glomset, J. A., Janssen, E. T., Kennedy, R., & Dobbins, J. (1966). Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins. *Journal Lipid Research*, 7, 639–648.
- Grefhorst, A., Hoekstra, J., Derks, T. G. J., Ouwens, D. M., Baller, J. F. W., Havinga, R., Kuipers, F. (2005). Acute hepatic steatosis in mice by blocking β -oxidation does not reduce insulin sensitivity of very-low- density lipoprotein production. *American Journal of Physiology - Gastrointestinal and Liver Physiology*, 289(352–353).

- Gill, S., Stevenson, J., Kristiana, I., & Brown, A. J. (2011). Cholesterol-Dependent Degradation of Squalene Monooxygenase, a Control Point in Cholesterol Synthesis beyond HMG-CoA Reductase. *Cell Metabolism*, 13(3), 260–273.
- Gill, P. K., Dron, J. S., Berberich, A. J., Wang, J., McIntyre, A. D., Cao, H., & Hegele, R. A. (2021). Combined hyperlipidemia is genetically similar to isolated hypertriglyceridemia. *Journal of Clinical Lipidology*, 15(1), 79–87.
- Gounden, V., Bhatt, H., & Jialal, I. (2021). Renal Function Tests. StatPearls. Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK507821/>
- Gowda, S., Desai, P. B., Kulkarni, S. S., Hull, V. V., Math, A. A. K., & Vernekar, S. N. (2010). Markers of renal function tests. *North American Journal of Medical Sciences*, 2(4), 170.
- Goyal, R. K., & Kadnur, S. V. (2006). Beneficial effects of Zingiber officinale on goldthioglucose induced obesity. *Fitoterapia*, 77(3), 160–163.
- Han, L. K., Morimoto, C., Zheng, Y. N., Li, W., Asami, E., Okuda, H., & Saito, M. (2008). Effects of zingerone on fat storage in ovariectomized rats. *Yakugaku Zasshi*, 128(8), 1195–1201.
- Han, Q., Yeung, S. C., Ip, M. S. M., & Mak, J. C. W. (2018). Dysregulation of cardiac lipid parameters in high-fat high-cholesterol diet-induced rat model. *Lipids in Health and Disease*, 17(1), 1–10.
- Hegazi, A. G., & Abd El-Hady, F. K. (2009). Influence of honey on the suppression of human low density lipoprotein (LDL) peroxidation (in vitro). *Evidence-Based Complementary and Alternative Medicine*, 6(1), 113–121.
- Hill, M. F., & Bordonni, B. (2022). Hyperlipidemia. StatPearls. Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK559182/>
- Hosseini, A., & Hosseinzadeh, H. (2015). A review on the effects of *Allium sativum* (Garlic) in metabolic syndrome. *Journal of endocrinological investigation*, 38(11), 1147–1157.
- Huff, T., & Jialal, I. (2018). Physiology, Cholesterol In: Anonymous StatPearls. Treasure Island (FL): StatPearls Publishing LLC. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/29262185>
- Istvan, E. S., & Deisenhofer, J. (2001). Structural Mechanism for Statin Inhibition of HMG-CoA Reductase. *Science*, 292(5519), 1160–1164.
- Jørgensen, T., Capewell, S., Prescott, E., Allender, S., Sans, S., Zdrojewski, T., Vanuzzo, D. (2013). Population-level changes to promote cardiovascular health. *European Journal of Preventive Cardiology*, 20(3), 409–421.
- Karam, I., Yang, Y. J., & Li, J. Y. (2017). Hyperlipidemia Background and Progress. *SM Atherosclerosis Journal*, 1(1), 1–8.

- Kim, J. H., Byun, J. C., Bandi, A. K. R., Hyun, C. G., & Lee, N. H. (2009). Compounds with elastase inhibition and free radical scavenging activities from *Callistemon lanceolatus*. *Journal of Medicinal Plants Research*, 3(11), 914–920.
- Kim, I., Kim, H. R., Kim, J. H., & Om, A. S. (2013). Beneficial effects of *alliumsativum* L. stem extract on lipid metabolism and antioxidant status in obese mice fed a high-fat diet. *Journal of the Science of Food and Agriculture*, 93(11), 2749–2757.
- Khezri, S. S., Saidpour, A., Hosseinzadeh, N., & Amiri, Z. (2018). Beneficial effects of Apple Cider Vinegar on weight management, Visceral Adiposity Index and lipid profile in overweight or obese subjects receiving restricted calorie diet: A randomized clinical trial. *Journal of Functional Foods*, 43, 95–102.
- Kunnen, S., & Van Eck, M. (2012). Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis? *Journal of Lipid Research*, 53(9), 1783–1799.
- Lasker, S., Rahman, M. M., Parvez, F., Zamila, M., Miah, P., Nahar, K., Alam, M. A. (2019). High-fat diet-induced metabolic syndrome and oxidative stress in obese rats are ameliorated by yogurt supplementation. *Scientific Reports* 2019 9:1, 9(1), 1–15.
- Lee, R. G., Kelley, K. L., Sawyer, J. K., Farese, R. V., Parks, J. S., & Rudel, L. L. (2004). Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential. *Circulation Research*, 95(10), 998–1004.
- Lee, R. G., Shah, R., Sawyer, J. K., Hamilton, R. L., Parks, J. S., & Rudel, L. L. (2005). ACAT2 contributes cholesteryl esters to newly secreted VLDL, whereas LCAT adds cholesteryl ester to LDL in mice. *Journal of Lipid Research*, 46(6), 1205–1212.
- Li W, Wu N, Shu W, Jia D, J. P. (2015). Pharmacological preconditioning and postconditioning with nicorandil attenuates ischemia/reperfusion- induced myocardial necrosis and apoptosis in hypercholesterolemic rats. *Exp Ther Med.*, 10, 2197–205.
- Lipsy, R. J. (2003). The National Cholesterol Education Program Adult Treatment Panel III Guidelines. *Journal of Managed Care Pharmacy*, 9(1), 2–5.
- Ma, H. (2004). Cholesterol and Human Health. *Nature and Science*, 2(4), 17–21.
- Mantena, S. K., King, A. L., Andringa, K. K., Eccleston, H. B., & Bailey, S. M. (2008). Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol-and obesity-induced fatty liver diseases. *Free Radical Biology and Medicine*, 44(7), 1259-1272.

- Woo, M. N., Bok, S. H., Lee, M. K., Kim, H. J., Jeon, S. M., Do, G. M., & Choi, M. S. (2008). Anti-obesity and hypolipidemic effects of a proprietary herb and fiber combination (S&S PWH) in rats fed high-fat diets. *Journal of medicinal food*, 11(1), 169-178.
- Miller, J. D., Weiss, R. M., Serrano, K. M., Brooks, R. M., Berry, C. J., Zimmerman, K., & Heistad, D. D. (2009). Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. *Circulation*, 119(20), 2693-2701.
- Mikaili, P., Maadirad, S., Moloudizargari, M., Aghajanshakeri, S., & Sarahroodi, S. (2013). Therapeutic uses and pharmacological properties of garlic, shallot, and their biologically active compounds. *Iranian journal of basic medical sciences*, 16(10), 1031.
- Murkovic, M., Abuja, P. M., Bergmann, A. R., Zirngast, A., Adam, U., Winklhofer-Roob, B. M., & Toplak, H. (2004). Effects of elderberry juice on fasting and postprandial serum lipids and low-density lipoprotein oxidation in healthy volunteers: A randomized, double-blind, placebo-controlled study. *European Journal of Clinical Nutrition*, 58(2), 244-249.
- Münstedt, K., Hoffmann, S., Hauenschild, A., Bülte, M., Von Georgi, R., & Hackethal, A. (2009). Effect of honey on serum cholesterol and lipid values. *Journal of Medicinal Food*, 12(3), 624-628.
- Monetti, M., Levin, M. C., Watt, M. J., Sajan, M. P., Marmor, S., Hubbard, B. K., Farese, R. V. (2007). Dissociation of Hepatic Steatosis and Insulin Resistance in Mice Overexpressing DGAT in the Liver. *Cell Metabolism*, 6(1), 69-78.
- Mosqueda-Solís, A., Sánchez, J., Portillo, M. P., Palou, A., & Picó, C. (2018). Combination of capsaicin and hesperidin reduces the effectiveness of each compound to decrease the adipocyte size and to induce browning features in adipose tissue of western diet fed rats. *Journal of Agricultural and Food Chemistry*, 66(37), 9679-9689.
- Mothana, R. A. A., Abdo, S. A. A., Hasson, S., Althawab, F. M. N., Alaghbari, S. A. Z., & Lindequist, U. (2010). Antimicrobial, Antioxidant and Cytotoxic Activities and Phytochemical Screening of Some Yemeni Medicinal Plants. *Evidence-Based Complementary and Alternative Medicine: ECAM*, 7(3), 323.
- Naseem, E., Shamim, M., & Khan, N. I. (2016). Cardioprotective effects of herbal mixture (ginger, garlic, lemon, apple cider vinegar & honey) in experimental animal models of hyperlipidemia. *Int. J. Biol. Res*, 4(1), 28-33.
- Nickolas, T. L., Radhakrishnan, J., & Appel, G. B. (2003). Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. *Seminars in Nephrology*, 23(4), 406-411.

- Nelson, R. H. (2013). Hyperlipidemia as a Risk Factor for Cardiovascular Disease. *Primary Care - Clinics in Office Practice*, 40(1), 195–211.
- Nguyen, H. T. L., Panyoyai, N., Kasapis, S., Pang, E., & Mantri, N. (2019). Honey and Its Role in Relieving Multiple Facets of Atherosclerosis. *Nutrients*, 11(1).
- Onwe, P., Folawiyo, M., Ogah, A., Umahi, G., Okorochoa, A., & Afoke, A. (2015). Hyperlipidemia: Etiology and Possible Control. *IOSR Journal of Dental and Medical Sciences*, 14(10), 2279–2861.
- Ou, B., Hampsch-Woodill, M., & Prior, R. L. (2001). Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. *Journal of agricultural and food chemistry*, 49(10), 4619–4626.
- Perumal, K. V., Ja'afar, N. L., Balan, S. S., Zainal Abidin, A., Arapoc, D. J., Shafie, N. H., & Bahari, H. (2019). Preventive effect of *Elaeagnus argentea* seed extract against obese Sprague Dawley rats. *Oriental Pharmacy and Experimental Medicine*, 1–7.
- Ponmurugan K, S. R. (2012). Antibacterial effect of *Allium sativum* cloves and *Zingiber officinale* rhizomes against multiple-drug resistant clinical pathogens. *Asian Pac J Trop Biomed.*, 2, 597–601.
- Rafiq, S., Kaul, R., Sofi, S. A., Bashir, N., Nazir, F., & Nayik, G. A. (2018). Citrus peel as a source of functional ingredient: a review. *Journal of the Saudi Society of Agricultural Sciences*, 17(4), 351–358.
- Remaley, A. T., Amar, M., & Sviridov, D. (2008). HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. *Expert Review of Cardiovascular Therapy*, 6(9), 1203–1215.
- Repa, J. J., Buhman, K. K., Farese, R. V., Dietschy, J. M., & Turley, S. D. (2004). ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse: impact on hepatic cholesterol homeostasis. *Hepatology (Baltimore, Md.)*, 40(5), 1088–1097.
- Rosenson, R. S. (2008). Fenofibrate: treatment of hyperlipidemia and beyond. *Expert Review of Cardiovascular Therapy*, 6(10), 1319–1330.
- Rousset, X., Vaisman, B., Amar, M., Sethi, A. A., & Remaley, A. T. (2009). Lecithin:Cholesterol Acyltransferase: From Biochemistry to Role in Cardiovascular Disease. *Current Opinion in Endocrinology, Diabetes, and Obesity*, 16(2), 163.
- Rudel, L. L., Lee, R. G., & Parini, P. (2005). ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 25(6), 1112–1118.
- Samarghandian, S., Farkhondeh, T., & Samini, F. (2017). Honey and health: A review of recent clinical research. *Pharmacognosy Research*, 9(2), 121–127.

- Rizza, S., Muniyappa, R., Iantorno, M., Kim, J. A., Chen, H., Pullikotil, P., & Quon, M. J. (2011). Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. *The Journal of Clinical Endocrinology & Metabolism*, 96(5), E782-E792.
- Saravanan, G., Ponmurugan, P., Deepa, M. A., & Senthilkumar, B. (2014). Anti-obesity action of gingerol: effect on lipid profile, insulin, leptin, amylase and lipase in male obese rats induced by a high-fat diet. *Journal of the Science of Food and Agriculture*, 94(14), 2972-2977.
- Selvaraj, P., & Pugalend, K. V. (2012). Efficacy of hesperidin on plasma, heart and liver tissue lipids in rats subjected to isoproterenol-induced cardiotoxicity. *Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie*, 64(5), 449-452.
- Sen, S., Chakraborty, R., Sridhar, C., Reddy, Y. S. R., & De, B. (2010). Free radicals, antioxidants, diseases and phytomedicines: Current status and future prospect. *International Journal of Pharmaceutical Sciences Review and Research*, 3(1), 91-100.
- Setorki, M., Asgary, S., Eidi, A., Rohani, A. H., & Khazaei, M. (2010). Acute effects of vinegar intake on some biochemical risk factors of atherosclerosis in hypercholesterolemic rabbits. *Lipids in Health and Disease*, 9.
- Shattat, G. F. (2015). A review article on hyperlipidemia: types, treatments and new drug targets. *Biomedical and Pharmacology Journal*, 7(1), 399- 409.
- Sheeba, D. A. H., & Gandhimathi, R. (2021). An Overview on Hyperlipidemia. *Journal of Pharmaceutical Research International*, 543-555.
- Stancu, C., & Sima, A. (2001). Statins: mechanism of action and effects. *Journal of Cellular and Molecular Medicine*, 5(4), 378-387
- Sim, J., Hwang, S., & Song, C. (2018). Hyperlipidemia as a predictor of physical functioning for stroke. *Physical Therapy Rehabilitation Science*, 7(2), 88-93.
- Singleton, V. L., & Rossi, J. A. (1965). Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents. *American journal of Enology and Viticulture*, 16(3), 144-158.
- Singletary, K. (2010). Ginger: an overview of health benefits. *Nutrition Today*, 45(4), 171-183.
- Uehara, M. (2006). Prevention of osteoporosis by foods and dietary supplements. Hesperidin and lipid metabolism. *Clinical Calcium*, 16(10), 73-80.
- Verma, S., Gupta, M. L., Dutta, A., Sankhwar, S., Shukla, S. K., & Flora, S.

- J. S. (2010). Modulation of ionizing radiation induced oxidative imbalance by semi-fractionated extract of Piper betle: an in vitro and in vivo assessment. *Oxidative Medicine and Cellular Longevity*, 3(1), 44– 52.
- Verma, N. (2016). Introduction to hyperlipidemia and its treatment: a review. *International Journal of Current Pharmaceutical Research*, 9(1), 6. <https://doi.org/10.22159/ijcpr.2017v9i1.16616>
- Visavadiya, N. P., & Narasimhacharya, A. V. R. L. (2011). Ameliorative Effects of Herbal Combinations in Hyperlipidemia. *Oxidative Medicine and Cellular Longevity*, 2011
- Wagner, J. A., Larson, P. J., Weiss, S., Miller, J. L., Doebber, T. W., Wu, M. S., Gottesdiener, K. M. (2005). Individual and combined effects of peroxisome proliferator-activated receptor and γ agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. *Journal of Clinical Pharmacology*, 45(5), 504–513.
- Wang, Xinhui, Junichi Hasegawa, Yoshiyuki Kitamura, Zhongzhi Wang, Akiko Matsuda, Waka Shinoda, Norimasa Miura, and Koji Kimura. 2011. "Effects of Hesperidin on the Progression of Hypercholesterolemia and Fatty Liver Induced by High-Cholesterol Diet in Rats." *Journal of Pharmacological Sciences* 117 (3): 129–138.
- Weibel GL, Drazul-Schrader D, Shivers DK, Wade AN, Rothblat GH, Reilly MP, et al. (2014). Importance of evaluating cell cholesterol influx and efflux in determining the impact of human serum on cholesterol metabolism and atherosclerosis. *Arterioscler Thromb Vasc Biol.*, 34, 17– 25.
- Wilcox, L. J., Borradaile, N. M., De Dreu, L. E., & Huff, M. W. (2001). Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. *Journal of Lipid Research*, 42(5), 725–734.
- Wilkinson, M. J., Laffin, L. J., & Davidson, M. H. (2014). Overcoming toxicity and side-effects of lipid-lowering therapies. *Best Practice & Research. Clinical Endocrinology & Metabolism*, 28(3), 439–452.
- Willner, E. L., Tow, B., Buhman, K. K., Wilson, M., Sanan, D. A., Rudel, L. L., & Farese, R. V. (2003). Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. *Proceedings of the National Academy of Sciences of the United States of America*, 100(3), 1262–1267.
- World Health Organization. Global status report on noncommunicable diseases 2010. Geneva, World Health Organization, 2015.
- World Health Organization (2015). Raised cholesterol- Global health Observatory (GHO) data. Retrieved from https://www.who.int/gho/ncd/risk_factors/cholesterol_text/en/#:~:text=In%202008%20the%20global%20prevalence,decade%20in%20men%20and%20women.

- Wouters, K., Shiri-Sverdlov, R., van Gorp, P. J., van Bilsen, M., & Hofker, M. H. (2005, May). Understanding hyperlipidemia and atherosclerosis: Lessons from genetically modified apoe and ldlr mice. *Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med*.
- Wu, X., Beecher, G. R., Holden, J. M., Haytowitz, D. B., Gebhardt, S. E., & Prior, R. L. (2004). Lipophilic and hydrophilic antioxidant capacities of common foods in the United States. *Journal of Agricultural and Food Chemistry*, 52(12), 4026–4037.
- Yaghoobi, N., Al-Waili, N., Ghayour-Mobarhan, M., Parizadeh, S. M. R., Abasalti, Z., Yaghoobi, Z., Ferns, G. A. A. (2008). Natural honey and cardiovascular risk factors; effects on blood glucose, cholesterol, triacylglycerole, CRP, and body weight compared with sucrose. *TheScientificWorldJournal*, 8, 463–469.
- Yap, C. Y. F., & Aw, T. C. (2010). Liver function tests (LFTs). *Proceedings of Singapore Healthcare*, 19(1), 80–82.
- Xenoulis, P. G., & Steiner, J. M. (2010). Lipid metabolism and hyperlipidemia in dogs. *The Veterinary Journal*, 183(1), 12–21.
- Xie, N., Cui, Y., Yin, Y. N., Zhao, X., Yang, J. W., Wang, Z. G., ... Lu, F. G. (2011). Effects of two *Lactobacillus* strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet. *BMC Complementary and Alternative Medicine*, 11.
- Xu, Q. Y., Liu, Y. H., Zhang, Q., Ma, B., Yang, Z. D., Liu, L., & Wu, Z. M. (2014). Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats. *Acta Pharmacologica Sinica*, 35(10), 1265-1273.
- Zeka, K., Ruparelia, K., Arroo, R. R. J., Budriesi, R., & Micucci, M. (2017). Flavonoids and Their Metabolites: Prevention in Cardiovascular Diseases and Diabetes. *Diseases*, 5(3), 19.
- Zheng, S., Lizbeth Hoos, Cook, J., Tetzloff, G., Jr, H. D., Heek, M. van, & Hwa, J. J. (2008). Ezetimibe improves high fat and cholesterol diet- induced non-alcoholic fatty liver disease in mice. *European Journal of Pharmacology*, 584(1), 118–124.
- Zhou, L., Li, C., Gao, L., & Wang, A. (2015). High-density lipoprotein synthesis and metabolism. *Molecular medicine reports*, 12(3), 4015- 4021.
- Zodda, D., Giammona, R., & Schifilliti, S. (2018). Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. *Pharmacy*, 6(1), 10.